MADRIGAL PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Increase (Decrease) in Deferred Revenue of -$6.73 million for the 12-month period ending 2011-12-31, per its 10-K filed 2014-03-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2014-03-11
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2011-12-31 was -$3.30M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2011-09-30 was -$1.14M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2011-06-30 was -$1.14M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2011-03-31 was -$1.14M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2011 was -$6.73M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2010 was -$4.65M.
- MADRIGAL PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2009 was -$115.63M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-11 | -$4.45M derived: sum of 2 quarters · filed 2014-03-11 | -$5.59M derived: sum of 3 quarters · filed 2014-03-11 | -$6.73M 10-K · filed 2014-03-11 |
| 2011-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$2.29M derived: sum of 2 quarters · filed 2012-11-06 | -$3.43M 10-Q · filed 2012-11-06 | -$4.57M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-06-30 | -$1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | -$2.29M 10-Q · filed 2012-08-02 | -$3.43M derived: sum of 3 quarters · filed 2013-03-14 | -$4.57M derived: sum of 4 quarters · filed 2013-03-14 |
| 2011-03-31 | -$1.14M 10-Q · filed 2012-05-03 | -$2.29M derived: sum of 2 quarters · filed 2013-03-14 | -$3.43M derived: sum of 3 quarters · filed 2013-03-14 | |
| 2010-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-14 | -$2.29M derived: sum of 2 quarters · filed 2013-03-14 | -$4.65M 10-K · filed 2013-03-14 | |
| 2010-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$3.50M 10-Q · filed 2011-11-03 | ||
| 2010-06-30 | -$2.36M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | -$115.63M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |